Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

21 Jan 2021

Psyched Wellness Submits an Application to Register a Trademark for the Company’s Unique Extraction

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

20 Jan 2021

Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector

MIAMI, Jan....

By Microdose

Press Releases

20 Jan 2021

Revive Therapeutics Announces $10 Million Bought Deal Offering of Units

TORONTOJan....

By Microdose

Press Releases

20 Jan 2021

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

BASEL, SwitzerlandJan....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

19 Jan 2021

PSYC Completes Execution of JV Partnership with Digital Mental Health Startup, PsycheDev Inc.

PSYC Looks to Capitalize on Growing Momentum Within the Digital Mental Health Sector LAS VEGAS, NV, Jan....

By Microdose

Press Releases

19 Jan 2021

Cybin Announces Upsize to Previously Announced Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Jan....

By Microdose

Press Releases

18 Jan 2021

Havn Life to support Canadian counterpart of Veterans’ organization Heroic Hearts

Havn Life to grow its partnership with the US-based veterans’ organization by funding and supporting the launch of its Canadian counterpart....

By Microdose

Press Releases

18 Jan 2021

Cybin Announces CDN$20 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTOJan....

By Microdose

Press Releases

14 Jan 2021

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORKJan....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.